Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $150.00

Sarepta Therapeutics (NASDAQ:SRPT) had its target price upped by Guggenheim from $148.00 to $150.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

SRPT has been the subject of a number of other research reports. UBS Group boosted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a research note on Thursday. Evercore ISI decreased their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Raymond James restated an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Buy” and a consensus price target of $181.33.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $121.61 on Thursday. Sarepta Therapeutics has a one year low of $75.85 and a one year high of $173.25. The company has a market cap of $11.60 billion, a PE ratio of 97.29 and a beta of 0.81. The stock has a 50-day moving average of $125.92 and a 200-day moving average of $132.91. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 11.72% and a net margin of 7.43%. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same quarter last year, the firm posted ($0.27) earnings per share. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. On average, equities research analysts predict that Sarepta Therapeutics will post 1.48 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, Director Michael Andrew Chambers bought 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in SRPT. Commonwealth Equity Services LLC lifted its holdings in Sarepta Therapeutics by 8.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock worth $679,000 after purchasing an additional 418 shares in the last quarter. PFG Advisors bought a new position in shares of Sarepta Therapeutics in the first quarter valued at approximately $591,000. Oppenheimer Asset Management Inc. grew its stake in Sarepta Therapeutics by 32.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company’s stock valued at $467,000 after acquiring an additional 874 shares in the last quarter. Swiss National Bank increased its holdings in Sarepta Therapeutics by 6.3% during the 1st quarter. Swiss National Bank now owns 166,183 shares of the biotechnology company’s stock worth $21,514,000 after acquiring an additional 9,900 shares during the period. Finally, Sei Investments Co. lifted its stake in Sarepta Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 61,451 shares of the biotechnology company’s stock worth $7,956,000 after purchasing an additional 5,332 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.